Overview

BI 409306 Cardiac Safety Trial in Healthy Volunteers

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This trial will be conducted to further evaluate, in a controlled setting, potential cardiac effects of an anticipated therapeutic and supra-therapeutic dose of BI 409306 under resting and exercise conditions. Since the drug is being developed in part for a disease with an expectedly high number of elderly (AD), the characterization of cardiac safety of BI 409306 is considered to be important for the development of this compound. This trial will be conducted to further evaluate, in a controlled setting, potential cardiac effects of an anticipated therapeutic and supra-therapeutic dose of BI 409306 under resting and exercise conditions. Since the drug is being developed in part for a disease with an expectedly high number of elderly (AD), the characterization of cardiac safety of BI 409306 is considered to be important for the development of this compound.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
BI 409306